Sotera Health (NASDAQ:SHC – Free Report) had its price objective decreased by Barclays from $22.00 to $20.00 in a report published on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.
A number of other research firms have also recently issued reports on SHC. JPMorgan Chase & Co. cut shares of Sotera Health from a “neutral” rating to an “underweight” rating and set a $17.00 price target for the company. in a report on Wednesday, October 14th. Weiss Ratings downgraded shares of Sotera Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Wall Street Zen raised shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, October 25th. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price on shares of Sotera Health in a research report on Tuesday, September 8th. Finally, Citigroup raised their target price on Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.
Get Our Latest Report on Sotera Health
Sotera Health Price Performance
Shares of SHC stock opened at $16.39 on Wednesday. Sotera Health has a fifty-two week low of $13.09 and a fifty-two week high of $19.85. The company has a debt-to-equity ratio of 2.90, a quick ratio of 2.55 and a current ratio of 3.13. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of 18.22 and a beta of 1.94. The stock’s 50-day simple moving average is $18.36 and its 200-day simple moving average is $17.00.
Sotera Health (NASDAQ:SHC – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. The firm had revenue of $324.89 million during the quarter, compared to analyst estimates of $319.86 million. Sotera Health had a net margin of 14.11% and a return on equity of 38.46%. Sotera Health’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS. As a group, equities analysts forecast that Sotera Health will post 0.87 earnings per share for the current fiscal year.
Insider Buying and Selling at Sotera Health
In other Sotera Health news, Chairman Michael B. Jr. Petras sold 850,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the sale, the chairman directly owned 3,969,393 shares of the company’s stock, valued at approximately $73,433,770.50. This trade represents a 17.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael P. Rutz sold 150,000 shares of Sotera Health stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $18.84, for a total value of $2,826,000.00. Following the transaction, the insider owned 334,279 shares of the company’s stock, valued at $6,297,816.36. The trade was a 30.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 1,294,515 shares of company stock worth $23,999,528. 15.36% of the stock is owned by corporate insiders.
Institutional Trading of Sotera Health
A number of hedge funds have recently modified their holdings of SHC. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sotera Health during the 3rd quarter worth about $29,000. Meeder Asset Management Inc. purchased a new position in shares of Sotera Health in the 2nd quarter valued at about $37,000. Root Financial Partners LLC increased its stake in shares of Sotera Health by 217.5% in the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company’s stock valued at $30,000 after purchasing an additional 1,455 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new position in Sotera Health in the 3rd quarter worth about $42,000. Finally, Nykredit A S acquired a new position in Sotera Health in the 2nd quarter worth about $50,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.
Key Sotera Health News
Here are the key news stories impacting Sotera Health this week:
- Positive Sentiment: For Q3 2026, revenue rose 4.4% year over year to $324.9 million, topping estimates of $319.9 million. Adjusted EPS of $0.29 also beat the $0.27 consensus and increased 12% from a year earlier—results that helped drive a strong post-earnings response. Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
- Positive Sentiment: Management reaffirmed its 2026 outlook: constant-currency revenue growth of 5.25%–6.75% and adjusted EBITDA growth of 5.75%–7.25%. This supports confidence in the full-year plan, although European medical-device market softness remains a concern. Sotera Health reaffirms 2026 outlook
- Neutral Sentiment: Barclays lowered its price target from $22 to $20 but maintained an “overweight” rating, leaving its view bullish while indicating a more cautious valuation outlook. Barclays recommendations
- Negative Sentiment: JPMorgan cut its target from $17 to $15 and moved to an “underweight” rating, signaling downside concerns and potentially weighing on sentiment. Tickerreport.com analyst update
About Sotera Health
Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.
The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.
Featured Articles
- Five stocks we like better than Sotera Health
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
